#USA #St. Louis #IceCure Medical #ProSense® #Shero Imaging

IceCure Medical's Groundbreaking Cryoablation in Missouri

On February 11, 2026, IceCure Medical Ltd. announced a pivotal development in breast cancer treatment with the introduction of the ProSense® cryoablation system at Shero Imaging in St. Louis, Missouri. This remarkable advancement positions Shero Imaging as the first clinic in the state to provide this innovative, minimally invasive option for patients with low-risk breast cancer.

The ProSense® system, which utilizes a unique cryoablation process, has received FDA marketing authorization, allowing it to be used in conjunction with endocrine therapy for women aged 70 and above. It represents a significant stride forward, particularly for those not suitable for surgical options. This system leverages liquid nitrogen efficiently to achieve effective tumor destruction, creating large lethal zones that have been optimized for safety and efficacy in both benign and malignant conditions.

A Game-Changer in Treatment

Dr. Tish Singer, the founder of Shero Imaging and a certified breast radiologist, expressed her excitement about bringing this advanced technology to the forefront of patient care. "Shero Imaging is transforming the way we approach breast cancer treatment by making innovative procedures like cryoablation easily accessible. Our focus remains on providing a comfortable, patient-centered environment while employing the highest standards of care," she stated.

The integration of ProSense® into Shero Imaging's offerings is particularly noteworthy in that it goes beyond traditional imaging services into proactive treatment solutions. Dr. Singer emphasized that this technology enables healthcare professionals to immediately address tumors, halting their progress through non-invasive methods.

Shero Imaging's decision to pioneer this treatment aligns seamlessly with IceCure Medical's mission to promote less invasive alternatives to surgery. Shad Good, IceCure's Vice President of Sales for North America, praised Shero Imaging for their role in advancing breast cancer therapies. He noted, "Breast radiologists are uniquely positioned to integrate the ProSense® system into their practices, enabling swift responses to low-risk breast cancer and related conditions such as fibroadenomas. We commend their initiative to make this remarkable treatment option available to local women."

Understanding ProSense®

The ProSense® Cryoablation System is distinct not only in its FDA approval but also in its design and application. This portable system allows for rapid, office-based procedures, crucial in a healthcare environment where efficiency and patient comfort are paramount. By minimizing post-procedural pain and reducing overall recovery times, the ProSense® system enhances the experiences of both patients and providers.

ProSense® targets several types of tumors, including those in the breast, kidney, lung, and liver, making it a versatile tool in the arsenal against cancer. The goal is to provide effective tumor destruction while promoting a quick return to daily activities for patients. The commitment to less invasive care is especially important for older patients or those presenting additional health challenges that contraindicate surgical options.

The Future of Treatment in St. Louis

With the launch of cryoablation services at Shero Imaging, IceCure Medical is not only expanding its reach but also encouraging a paradigm shift in breast cancer treatment. The introduction of advanced technologies coupled with a dedicated team of specialists promises to lead to improved health outcomes and enhanced quality of life for women diagnosed with breast cancer.

As Shero Imaging sets a precedent in Missouri, patients will have greater access to state-of-the-art treatment options, showcasing the importance of innovation in the ever-evolving landscape of healthcare. The steps taken by IceCure Medical and Shero Imaging emphasize a shared vision: to advance cancer treatment methods and improve patient care across the board.